Lumefantrine and Octreotide Injection: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Lumefantrine
No brand names on recordOctreotide Injection
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
An increased risk of QT interval prolongation
Interaction Deep Dive
Avoid coadministration of artemether/lumefantrine and drugs that prolong QT interval, such as octreotide2, due to the potential for additive effects on QT interval prolongation and an increased risk of serious cardiac events, including torsade de pointes 1. If concomitant administration of artemether/lumefantrine and QT prolonging agent is medically required, and monitor the ECG. Additionally, caution is advised when administering drugs that prolong the QT interval after completing artemether/lumefantrine therapy due to the long half-life of lumefantrine (3 to 6 days) 2.
Why it happens (mechanism)
Additive effects on QT interval prolongation
Common questions
Can I take Lumefantrine and Octreotide Injection together?
An increased risk of QT interval prolongation Always confirm with your pharmacist or prescriber before making any change.
How serious is the Lumefantrine and Octreotide Injection interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Lumefantrine or Octreotide Injection need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (2)
- Product Information: Sandostatin LAR(R) Depot IM injectable suspension, octreotide acetate IM injectable suspension. Novartis Pharmaceuticals Corporation (per FDA), East Hanover, NJ, 2011.
- Product Information: COARTEM® oral tablets, artemether lumefantrine oral tablets. Novartis Pharmaceuticals Corporation (per DailyMed), East Hanover, NJ, 2025. DailyMed
Keep reading about Lumefantrine
Keep reading about Octreotide Injection
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist